Glutathione
CAS 70-18-8
Glutathione (CAS 70-18-8) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 726 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 26554.821212121213 nM | 33 | - |
| - | IC50 | 55995.43666666667 nM | 5 | - |
| - | Potency | 19927.7 nM | 2 | - |
| - | EC50 | 50000 nM | 1 | - |
| Glutathione S-transferase kappa 1 Enzyme |
IC50 | 7.7 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hepatic function abnormal | 63 | 137.706 | 10019670 |
| Drug-induced liver injury | 40 | 73.659 | 10072268 |
| Incision site pain | 17 | 69.668 | 10058043 |
| Platelet count decreased | 57 | 64.018 | 10035528 |
| Lymphocyte count decreased | 32 | 62.04 | 10025256 |
| Neutrophil count increased | 26 | 56.406 | 10029368 |
| Alanine aminotransferase increased | 39 | 38.787 | 10001551 |
| Red blood cells urine positive | 11 | 34.72 | 10038182 |
| Eosinophilic pneumonia chronic | 7 | 34.516 | 10052833 |
| Chronic disease | 6 | 34.012 | 10076311 |
| Blood albumin decreased | 17 | 33.284 | 10005287 |
| White blood cell count increased | 25 | 30.91 | 10047943 |
| Bone marrow failure | 21 | 29.871 | 10065553 |
| Bowel movement irregularity | 11 | 29.077 | 10063541 |
| Aspartate aminotransferase increased | 30 | 27.362 | 10003481 |
| Defaecation urgency | 10 | 27.326 | 10012110 |
| White blood cell count decreased | 35 | 25.906 | 10047942 |
| Anaemia | 55 | 24.743 | 10002034 |
| Throat clearing | 7 | 22.523 | 10080125 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GLUTATHIONE | 4890 | SU | MTHSPL |
| glutathione | 4890 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Glutathione used for in pharmaceutical contexts?
Glutathione (CAS 70-18-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Glutathione?
Glutathione has 726 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Drug-induced liver injury, Incision site pain, Platelet count decreased, Lymphocyte count decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Glutathione also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glutathione with EU status "permitted".
What clinical phase is Glutathione in?
Glutathione is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Glutathione?
Glutathione has 5 bioactivity rows in this page query. Rendered target entries include Glutathione S-transferase kappa 1.